The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Voyxact
sibeprenlimab · SIBEPRENLIMAB 200 mg/mL · Injection · Subcutaneous · Otsuka America Pharmaceutical, Inc.
NDC 59148-0400-75 · 1 SYRINGE in 1 CARTON / 2 mL in 1 SYRINGE · BLA · View full market →
Medicare Part D
All Part D pricing →ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$14,315.20per unit
middle half $14,315.20–$14,317.46 · 52 plans · Apr 1, 2026
Est. net of rebatesⓘ
$8,589.12–$10,736.40
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
1%of plans cover it
tier 5 · prior auth 100% · step therapy 0% · qty limit 94%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 1 quarter since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$30,000.00
Reported to Texas DSHS · 2026 annual filing · Otsuka America Pharmaceutical, Inc.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 3 of 6 public criteria. Why that matters →
- Part D specialty tier · median tier 5 across plans
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA761434
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of sibeprenlimab (Injection)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | SIBEPRENLIMAB 200 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Voyxact — NDC 59148-0400-75," retrieved September 3, 2026, https://drugdashboards.com/drug/59148040075.
Free to cite with attribution — see how the data is put together.